Form 4: Viridian Therapeutics Director Granted Stock Options, Disclaims Beneficial Ownership

Viridian Therapeutics, Inc. Director Tomas Kiselak was granted 21,000 stock options with an exercise price of $14.47, vesting by July 2026, with beneficial ownership disclaimed due to an arrangement with Fairmount Funds Management LLC.

Summary

• Tomas Kiselak, a Director of Viridian Therapeutics, Inc. (VRDN), was granted 21,000 stock options.
• The stock options have an exercise price of $14.47 per share.
• The earliest transaction date for this grant was July 1, 2025.
• The options vest in full upon the earlier of July 1, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to Kiselak's continued service on the Board of Directors.
• The options are set to expire on July 1, 2035.
• Kiselak holds these options for one or more investment vehicles managed by Fairmount Funds Management LLC and is obligated to turn over any net cash or stock received to the Adviser for the benefit of such Fairmount Fund.
• Kiselak disclaims beneficial ownership of the option and underlying common stock.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued alignment between the board and shareholder interests, providing an incentive for long-term value creation. It is a standard, expected transaction.

Positives

• The granting of stock options aligns the director's interests with shareholder value creation by incentivizing long-term company performance.
• The options have a long expiration date of July 1, 2035, providing a significant window for potential value realization.

Negatives

• No direct negatives are apparent from this standard stock option grant.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The stock options are set to vest in full by July 1, 2026, or the Issuer's 2026 annual meeting of stockholders, contingent on the director's continued service on the Board.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industry, aligning executive incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• This Form 4 reports a standard stock option grant to a director, which is a common compensation practice across publicly traded companies, particularly in the biotech sector. Specific comparisons to other companies' compensation packages would require detailed analysis of their proxy statements (DEF 14A) and compensation philosophies, which are not provided in this filing.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are disclosed in this Form 4 filing.

Related Party Transactions

• Tomas Kiselak holds the options for one or more investment vehicles managed by Fairmount Funds Management LLC, and is obligated to turn over any net cash or stock received to the Adviser for the benefit of such Fairmount Fund. Kiselak disclaims beneficial ownership.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially incentivizing decisions that enhance long-term stock value.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• Continued service of Tomas Kiselak on the Board of Directors of Viridian Therapeutics, Inc.
• Vesting of the 21,000 stock options by July 1, 2026, or the 2026 annual meeting of stockholders.
• Potential exercise of the options by Tomas Kiselak (or Fairmount Fund) before July 1, 2035.

Key Dates

Keywords

Viridian Therapeutics, VRDN, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Tomas Kiselak, Fairmount Funds